Braveheart Investment Group PLC (AIM:BRH)’s investee Kirkstall has developed an ‘organ on a chip’ model of an innovative, milli-fluidic system, human blood-brain barrier which has been used to map the interaction between the blood-brain barrier and brain cancer.
Developed using Kirkstall's Quasi Vivo platform, it marks the first time a dynamic milli-fluidic model has been developed where the interactions between the blood-brain barrier and medulloblastoma brain cancer spheroids have been demonstrated.
The model was made in conjunction with the Biomedical Ultrasonics, Biotherapy and Biopharmaceutical Laboratory within the Institute of Biomedical Engineering at the University of Oxford,
It will enable the observation of the in vitro performance of drugs designed for treating brain cancer and central nervous system diseases such as Alzheimer's.
Braveheart holds an 86.11% equity interest in Kirkstall, as well as providing unsecured interest-free loans to Kirkstall totalling £10,752 as of March 31.
Trevor Brown, chief executive of Braveheart Investment Group, commented: "It is exciting to observe how collaboration between Kirkstall and Oxford University has resulted in an innovative and important application for the Quasi Vivo platform."